https://www.cellmabs.com/home daily 1.0 2024-01-09 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/5246aa79-551a-4621-bd23-731556d5544e/lab+image.png https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/05755261-4b43-4a43-ac8a-d1ef6fc8e298/Modalities+Antibodies Home - For the first time ever, researchers at CellmAbs have generated humanized antibodies with unprecedented specificity, and binding capability to glycan targets only expressed on cancer cells. It is now possible to develop anti-cancer therapies in different modalities, capable of effectively addressing several types of solid tumors and in several stages of Cancer. We have generated a panel of novel mAbs with different features to enable fine-tuning of targeted therapies: Binding; Affinity; Internalization (low, intermediate and high). https://www.cellmabs.com/board-directors daily 0.75 2022-05-29 https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624074-LIFE3HWUD6IQGF1F8SN2/20140228_Trade+151_0046.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624087-74OMW7C0NA8KXGH95OL7/Aro+Ha_0428.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624100-YU3KF80MMQ9WXMFY8OS1/Large+JPG-Aro+Ha_0387.jpg Team https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653832223990-7XB6SDZIK3QL48RHBBV4/IMG_8448-c%C3%B3pia.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624457-KBYAMJCPDM2H2X3U1085/Rectangle+26.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624465-F3OJ7NY6GFYLS9SYCZPJ/Rectangle+25.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624474-TQ4IL3BCKDLINWH58Z82/Rectangle+27.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624483-NFNCYTBJDG5GEXKX4LGM/Rectangle+25.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624490-JCYPHNLK778NZ53PS5NS/Rectangle+27.jpg Team https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835624498-K0V8UMWX5F5NWNX8TGSY/Rectangle+26.jpg Team https://www.cellmabs.com/adc daily 0.75 2022-06-09 https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835623683-OGUGYWJ1W63QTAOSZTMB/20140301_Trade-151_012-2.jpg Targeted Therapies https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835623697-KJ8RJ8U4GVTOGSXBL0FO/20140228_Trade+151_0046.jpg Targeted Therapies https://images.squarespace-cdn.com/content/v1/5ec8261a74c0e67719117399/1623835623716-EUIKXV9B0DVV7ORVS2EZ/Aro+Ha_0428.jpg Targeted Therapies https://www.cellmabs.com/contactus daily 0.75 2022-05-30 https://www.cellmabs.com/science daily 0.75 2022-05-30 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/71bf9fb1-93ec-4e78-abeb-676d2efc31df/Glycan+Binding Science - Breaking the glycan shield of solid tumors Most cancer cells on solid tumors are characterized by the expression of antigens such as aberrant glycans that confer increased malignancy to the cells. This expression has been suggested to be associated with patients' low survival. Studies have shown that specific glycans induce an immunosuppressive phenotype on immune cells while cancer cells expressing these antigens present malignant features associated with poor prognosis and reduced overall survival. These antigens are restricted to cancer cells, making these the most suitable targets when treating several types of solid tumors. https://www.cellmabs.com/pipeline daily 0.75 2022-05-30 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/3ed9a512-ff5a-47d7-85cf-03e29e20160c/PipelineA.jpg Pipeline - Programs in development CellmAbs has been developing several therapeutic modalities targeting cancer-specific glycans using a unique mAb development platform. We develop innovative solutions to provide the most effective treatments to patients, and we are partnering with biotech/pharma companies and international clinical institutes. Last updated: May, 2022 https://www.cellmabs.com/privacy-policy daily 0.75 2022-05-30 https://www.cellmabs.com/people daily 0.75 2022-10-11 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653915220474-LAE8A6CBBCCCYMS69IS6/PaulaVideira2.jpeg People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653915655260-AJWVCLMP4KOTCMIBS1LF/RPH%2BLIn.jpg People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653915907217-8ADL6SHE4GETPM1CX7JE/Pat_foto.png People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653916189030-XLH9VGQ895TIREWY1S8V/Eliot+F.+.jpeg People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653916382938-W76JM2BCF9JRT7W8ALIY/Ravi.jpeg People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653916510627-S6VVJPVC2EN2NSMXTDMR/Bernardes.jpeg People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653916713040-D1JS4JSULE5A3MTNLA6S/L%C3%BAcio-Lara-Santos.png People https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/96226556-2acd-4df2-9337-0409fa54c746/NPR_-removebg-preview.png People https://www.cellmabs.com/about-1 daily 0.75 2022-10-25 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/7f24d0e5-9245-4b36-baad-a10d4efa5695/POCentro_PT2020_FEDER_Bom.jpg https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653912273242-UQRGMFBVCMY1CS7BMPJQ/Logo+BionovaCapital1.png About Us https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653912356067-SHMGNKU4R0HR6V3K1LI4/Logo_Portugal_Ventures_RGB-01.png About Us https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653831145303-72D2AQIWUA0V9A6TJM58/FCT+NOVA.jpeg About Us https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653831241858-HHHKTCCY6PKR2MHMIUQG/CEDOC.jpeg About Us https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/1653933987447-Q8G9DRLGSKG5MP2DLJO1/IPO+Porto.jpeg About Us https://www.cellmabs.com/news daily 0.75 2024-02-01 https://www.cellmabs.com/p2020covid-fdr daily 0.75 2022-10-25 https://images.squarespace-cdn.com/content/v1/629261336563a561e7a394ed/7f24d0e5-9245-4b36-baad-a10d4efa5695/POCentro_PT2020_FEDER_Bom.jpg https://www.cellmabs.com/nova-pgina-1 daily 0.75 2022-10-25 https://www.cellmabs.com/nova-pgina-2 daily 0.75 2022-10-25 https://www.cellmabs.com/terms-and-conditions daily 0.75 2022-10-25 https://www.cellmabs.com/faqs daily 0.75 2022-10-25 https://www.cellmabs.com/free-trial daily 0.75 2025-05-12 https://www.cellmabs.com/booking daily 0.75 2025-05-12 https://www.cellmabs.com/membership-subscriptions daily 0.75 2025-05-12 https://www.cellmabs.com/membership-subscriptions/p/plan-3-lwt98 monthly 0.5 2022-01-17 https://images.squarespace-cdn.com/content/v1/5f4faf5e64fafa7c3499f6cc/1599057795771-ONFBZD8W2I62LCEKVLY4/2888448+%281%29.jpg Assinaturas de adesão - Plano 3 https://www.cellmabs.com/membership-subscriptions/p/plan-2-k3pz8 monthly 0.5 2022-01-17 https://images.squarespace-cdn.com/content/v1/5f4faf5e64fafa7c3499f6cc/1599057794793-H1OK4EA79A786J8LE2L1/Stocksy_comp_2888472+%281%29.jpg Assinaturas de adesão - Plano 2 https://www.cellmabs.com/membership-subscriptions/p/plan-1-6mhx8 monthly 0.5 2022-01-17 https://images.squarespace-cdn.com/content/v1/5f4faf5e64fafa7c3499f6cc/1599057793716-O9G6KX3UJY6NBFYJ1UEZ/2888491+%281%29.jpg Assinaturas de adesão - Plano 1 - Imagem 1